The mitochondrial myopathies comprise a clinically heterogeneous group of disorders characterised by the accumulation of structurally abnormal mitochondria in skeletal muscle.1-3
Biochemical studies on mitochondria isolated from skeletal muscle have identified defects at a number of sites including complex I (NADHubiquinone reductase), complex III (ubiquinolcytochrome C oxido-reductase), complex IV (cytochrome oxidase), and ATPase. 3 The genetic basis of these disorders is uncertain.
Of particular interest is the occurrence of a high incidence of maternal transmission in some families.-5 Indeed, there is one extensive pedigree with nine affected subjects and exclusively maternal transmission not explicable by autosomal or X linked recessive inheritance, where the authors reported the probability of autosomal dominant inheritance to be as low as 0-0005. As mitochondrial DNA is maternally inherited,6 this observation led to the suggestion that the pattern of inheritance reflected the transmission of an abnormality within mitochondrial DNA.4 While the majority of components of the respiratory chain are encoded in the nucleus, the mitochondrial genome is known to code Received for publication 5 November 1987.
Revised version accepted for publication 25 9, respectively (fig 4a, c) . A double digest with HaeIII and HinfI suggests that the mutation creating the new HaeIII site is located at 10 097 base pairs (fig 4b) . Secondly, the normal 156 base HaeIII fragment was replaced by a 187 base fragment (fig 4a) , as has previously been described. 15 This is consistent with a HaeIII site loss at position 8995. In addition, digestion with BstNI and hybridisation with probe 10 (fig 4d) shows replacement of the normal 4713 and 1018 base fragments by two fragments of size 3608 and 2123 bases. This, again, suggests a BstNI site gain around 10 097, and a BstNI site loss around 8995. This indicates that the most likely point mutation at 10 097 is an A-G transition lying within the recognition sites of both HaeIII and BstNI. This is the third base in a codon in the reading frame of ND3 and would not result in an amino acid change. Similarly, the most likely cause of the BstNI and HaeIII site losses around 8994 is a G-A transition either at position 8994 or at 8995. The former is the third base in a codon in the reading frame of ATPase 6, and would not result in an amino acid change; the latter would result in replacement of alanine with threonine.
In patient 3, digestion with DdeI and hybridisation with probe 11 showed replacement of the 292 band by a 238 band. This site gain could be located at either 15 758 or 15 945, and the latter was excluded by obtaining normal restriction fragments with StyI. Thus, the most likely mutation is a G-A transition at 15 758, which would give rise to replacement of an isoleucine residue with valine.
Neither of these two amino acid changes is likely to affect the properties of the proteins substantially.1 However, their true location and significance must await further analysis by DNA sequencing and immunoelectrophoresis of protein products.
Two of the three new mutations found in this study were present in asymptomatic mothers of two patients and in one sib, and could therefore be uncommon population polymorphisms of no patho- 
